HEPA - Hepion Pharmaceuticals, Inc. Total Debt to Capital

Hepion Pharmaceuticals relies entirely on external contractors for molecule production and the conduct of trials. This price chart of the asset's market trend on the GURU.Markets platform captures the debt-to-equity ratio at 0.00. The business focuses on combating liver fibrosis and obesity through insurance payments while maintaining a highly specialized image within the scientific community.

This metric measures financial leverage by comparing total liabilities to net assets to assess the business's dependence on borrowed capital. By analyzing the total debt-to-equity ratio on GURU.Markets, an investor distinguishes temporary volatility from systemic risks, which is critical for Hepion Pharmaceuticals (HEPA), as its debt load determines viability until the company achieves monopoly pricing power over its drugs.